BIOANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF MARALIXIBAT IN RAT PLASMA BY LC-MS/MS DETECTION AND ITS APPLICATION TO A PHARMACOKINETIC STUDY
DOI:
https://doi.org/10.22159/ijap.2023v15i4.47768Keywords:
Maralixibat, Elobixibat, LC-MS/MS, Development and validation, Rat plasma, USFDAAbstract
Objective: To quantify maralixibat in rat plasma utilizing liquid-liquid extraction (LLE) approach, a practical, efficient, and accurate LC-MS/MS approach was devised.
Methods: As an internal standard (IS), Elobixibat was adopted. Utilizing an Agilent eclipse C18, 150 mm x 4.6 mm, 3.5 µm column, the drug separation was accomplished using an isocratic mobile phase entailing acetonitrile (ACN) and buffer (1 ml Tri fluoro acetic acid into 1liter water and stir well. Filtered through 0.22µ membrane filter paper) composition of 70:30 (v/v), dispensed at 1.0 ml/min.
Results: Multiple reaction monitoring (MRM) positive mode allowed for the simultaneous detection of maralixibat and elobixibat exhibiting proton adducts around m/z 676.0278-290.3625 and m/z 696.8541-480.6328, correspondingly. The correlation coefficient (r2) of the approach was ≥0.99977 across a linearity concentration spanning between 5.00–100.00 ng/ml. This technique achieved intra-day accuracy and precision between 99.31-100.93% and 0.22-6.55%, correspondingly. Across 3 freeze-thaw sessions, bench top testings, and postoperative stability investigations, maralixibat was shown to be stable.
Conclusion: Through intravenous injection, this approach was effectively utilized in rats for studying the drug's pharmacokinetics.
Downloads
References
US Food and Drug Administration. Livmarli TM (Maralixibat) US prescribing information; 2021. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213448s000lbl.pdf. [Last accessed on 03 Apr 2023]
Mirum Pharmaceuticals. Mirum Pharmaceuticals presents analyses from its rare liver disease programs at the EASL international liver congress; 2021. Available from: https://www.mirumpharma.com/news-events/press-releases/ detail/98/mirum-pharmaceuticals-presents-analyses-from-its-rare-liver-disease-programs-at-the-easl-international-liver-congress-2021. [Last accessed on 05 Apr 2022]
Shneider BL, Spino C, Kamath BM, Magee JC, Bass LM, Setchell KD. Placebo-controlled randomized trial of an intestinal bile salt transport inhibitor for pruritus in alagille syndrome. Hepatol Commun. 2018;2(10):1184-98. doi: 10.1002/hep4.1244. PMID 30288474.
Neimark E, Chen F, Li X, Shneider BL. Bile acid-induced negative feedback regulation of the human ileal bile acid transporter. Hepatology. 2004;40(1):149-56. doi: 10.1002/hep.20295, PMID 15239098.
US Food and Drug Administration. Livmarli (maralixibat) Corrected NDA Approval; 2021. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/213687Orig1s000CMAcorrltr.pdf. [Last accessed on 02 Apr 2023]
Mirum Pharmaceuticals. Mirum pharmaceuticals announces European medicines agency validation of the marketing authorization application for maralixibat in patients with PFIC2; 2020. Available from: https://ir.mirumpharma.com/news-releases/news-release-details/mirum-pharmaceuticals-announces-EuropeanMedicinesAgency. [Last accessed on 02 Apr 2023]
Mayo MJ, Pockros PJ, Jones D, Bowlus CL, Levy C, Patanwala I. A randomized, controlled, phase 2 study of Maralixibat in the treatment of itching associated with primary biliary cholangitis. Hepatol Commun. 2019;3(3):365-81. doi: 10.1002/hep4.1305, PMID 30859149.
Gonzales E, Hardikar W, Stormon M, Baker A, Hierro L, Gliwicz D. Efficacy and safety of Maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study. Lancet. 2021;398(10311):1581-92. doi: 10.1016/S0140-6736(21)01256-3, PMID 34755627.
Shirley M. Correction to: Maralixibat: first approval. Drugs. 2022;82(1):77. doi: 10.1007/s40265-021-01659-y, PMID 34870782.
Mirum Pharmaceuticals, Inc. Livmarli (maralixibat chloride) oral solution prescribing information. Foster City, CA; 2021. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214164s000lbl.pdf. [Last accessed on 02 Apr 2023]
Levy C. Evolving role of obeticholic acid in primary biliary cholangitis. Hepatology. 2018;67(5):1666-8. doi: 10.1002/hep.29726. PMID 29222924.
Arab JP, Karpen SJ, Dawson PA, Arrese M, Trauner M. Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives. Hepatology. 2017;65(1):350-62. doi: 10.1002/hep.28709, PMID 27358174.
Parmar I, Patel Ya. Recent method development by analytical techniques of new fda approved rugs in 2021. Int J Curr Pharm Sci. 2022;14(3, May):17-21. doi: 10.22159/ijcpr.2022v14i3.1975.
Guidance for industry: bioanalytical method validation. United States Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER); 2001. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioanalytical-method-validation. [Last accessed on 02 Apr 2023].
Kanchanamala K, Nagiat TH, Babu Rao C, Prakash K, Mukkanti K, Challa BR, Bhavyasri K. Bioanalytical method development and validation of milnacipran in rat plasma by LC–MS/MS detection and its application to a pharmacokinetic study. Journal of Pharmaceutical Analysis. 2013;3(6):481–8. doi: 10.1016/j.jpha.2013.05.006.
Namburi LA Amara Babu, Kalyani Koganti, Babji Palakeeti, Koduri SV Srinivas, Koya Prabhakara Rao. Bioanalytical LC-MS/MS method for determination and comparison of selexipag assay in various biological materials and its application to pharmacokinetics studies in rat plasma. IJRPS 2020;11(2):2210-20. doi: 10.26452/ijrps.v11i2.2172.
Puttagunta SB, Shaik RP, Bannoth CK, Challa BSR, Awen BZS. Bioanalytical method for quantification of solifenacin in rat plasma by LC-MS/MS and its application to pharmacokinetic study. J Anal Sci Technol. 2014;5(1):35. doi: 10.1186/s40543-014-0035-0.
Pravallika KE, Prameela Rani A, Ratna Kumar M. Bioanalytical method development and validation of Entrectinib in rat plasma by liquid-chromatography–tandem mass spectrometry. Asian J Pharm Clin Res. 2020;13(11):155-63. doi: 10.22159/ajpcr.2020.v13i11.39105.
Athavia BA, Dedania ZR, Dedania RR, Swamy SMV, Prajapati CB. Stability indicating HPLC method for determination of vilazodone hydrochloride. Int J Curr Pharm Sci. 2017;9(4). doi: 10.22159/ijcpr.2017v9i4.20975.
Sura RS, Cvs S, Rachamalla SS. Bioanalytical RP-HPLC method development and validation of clopidogrel bisulfate in Wistar rat plasma and its application to pharmacokinetic study. Int J App Pharm. 2022;14(1):106-11. doi: 10.22159/ ijap.2022v14i1.43328.
Rao KP, babu NL, Koganti K, Palakeeti B, Srinivas KSV. Related substances method development and validation of an LCMS/MS method for quantification of selexipag and its related impurities in rat plasma and its application to pharmacokinetic studies. SN Appl Sci. 2021;3(3). doi: 10.1007/s42452-021-04219-x.
Alumuri T, Merugu K, Amarababu NLA, Kurnool A. Peramivir and related impurities in rat plasma and its applications in pharmacokinetic studies (bioanalytical method development and validation by LC-MS/MS). Int J App Pharm 2022;14(5):53-61. doi: 10.22159/ijap.2022v14i5.45457.
Tijare LK, Nt R, Un M. A review on bioanalytical method development and validation. Asian J Pharm Clin Res 2016;9(9). doi: 10.22159/ajpcr.2016.v9s3.14321.
Gurav P, Damle M. Bioanalytical method for estimation of teriflunomidein human plasma. Int J Pharm Pharm Sci. 2022;Sep 1:19-23. doi: 10.22159/ijpps.2022v14i9.45151.
Sellappan M, Devakumar D. Development and validation of RP-HPLC method for the estimation of escitalopram oxalate and flupentixol dihydrochloride in combined dosage form and plasma. Int J Pharm Pharm Sci. 2021 Feb 1:61-6. doi: 10.22159/ijpps.2021v13i2.30158.
Published
How to Cite
Issue
Section
Copyright (c) 2023 MADHUSUDHANA REDDY NIMMAKAYALA, DEEPTI KOLLI, PASUPULETI NAVEENA DURGA BHAVANI
This work is licensed under a Creative Commons Attribution 4.0 International License.
